Incretin Therapy

Mechanism

Related News

Phase 3b trial reports positive results for Taltz-Zepbound psoriasis combo

May 13, 2026

Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.

Taltz and Zepbound Combination Achieves Superior Results in Psoriasis and Obesity Trial

Feb 18, 2026

Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.